On November 21st, according to Baiaozhihui, Baiaozhihui and its subsidiary Shanghai Xingsai Biotechnology Co., Ltd. recently signed an asset purchase agreement with Gilead Sciences Inc. According to the agreement, Gilead Sciences has obtained global equity in several preclinical anti-tumor candidate drug assets from Baiaozhihui, and has made down payments and milestone payments. Gilead Science will grant BAO Zhihui the preemptive right to purchase the above individual assets in Chinese Mainland.